Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Genmab announces Janssen's 'positive' results from Phase 3 APOLLO study » 15:40
07/31/20
07/31
15:40
07/31/20
15:40
GMAB

Genmab

$34.09 /

-0.96 (-2.74%)

, JNJ

Johnson & Johnson

$144.58 /

-2.29 (-1.56%)

Genmab A/S (GMAB)…

Genmab A/S (GMAB) announced that the European Myeloma Network in collaboration with Janssen Research & Development reported positive results from the Phase 3 APOLLO study of the subcutaneous formulation of daratumumab in combination with pomalidomide and dexamethasone versus Pd alone as treatment for patients with relapsed or refractory multiple myeloma who have previously been treated with lenalidomide and a proteasome inhibitor. The study met the primary endpoint of improving progression-free survival. Overall, the safety profile of daratumumab SC in combination with Pd was consistent with the safety profile for each therapy separately, Genmab stated. "We are pleased with these positive results for daratumumab, administered as a subcutaneous formulation, in combination with pomalidomide and dexamethasone. The corresponding intravenous regimen was previously approved by the U.S. FDA based on the Phase1 single-arm EQUULEUS study," said Jan van de Winkel, CEO of Genmab. Janssen Biotech (JNJ), which obtained an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab in 2012, intends to discuss the data with health authorities in preparation for regulatory submissions and plans to submit the data for presentation at an upcoming medical conference, Genmab stated.

ShowHide Related Items >><<
JNJ Johnson & Johnson
$144.58 /

-2.29 (-1.56%)

GMAB Genmab
$34.09 /

-0.96 (-2.74%)

GMAB Genmab
$34.09 /

-0.96 (-2.74%)

07/02/20 Societe Generale
Genmab initiated with a Sell at Societe Generale
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Guggenheim
Guggenheim says Seattle Genetics' cervical cancer data 'a positive surprise'
06/25/20 Credit Suisse
Genmab downgraded to Neutral from Outperform at Credit Suisse
JNJ Johnson & Johnson
$144.58 /

-2.29 (-1.56%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
JNJ Johnson & Johnson
$144.58 /

-2.29 (-1.56%)

GMAB Genmab
$34.09 /

-0.96 (-2.74%)

JNJ Johnson & Johnson
$144.58 /

-2.29 (-1.56%)

JNJ Johnson & Johnson
$144.58 /

-2.29 (-1.56%)

GMAB Genmab
$34.09 /

-0.96 (-2.74%)

JNJ Johnson & Johnson
$144.58 /

-2.29 (-1.56%)

Over a week ago
Hot Stocks
Genmab reports Q2 net sales of Darzalex $901M » 06:48
07/16/20
07/16
06:48
07/16/20
06:48
GMAB

Genmab

$36.05 /

+0.76 (+2.15%)

, JNJ

Johnson & Johnson

$148.32 /

+0.36 (+0.24%)

Genmab (GMAB) announced…

Genmab (GMAB) announced worldwide net sales of Darzalex - daratumumab -, including sales of the subcutaneous formulation, as reported by Johnson & Johnson (JNJ) were $901M in Q2. Net trade sales were $492M in the U.S. and $409M in the rest of the world. Genmab will receive royalties on the worldwide net sales of Darzalex under the exclusive worldwide license to Janssen Biotech to develop, manufacture and commercialize Darzalex. Darzalex is indicated for the treatment of adult patients in the U.S. in various combinations as treatment for patients newly diagnosed with multiple myeloma.

ShowHide Related Items >><<
JNJ Johnson & Johnson
$148.32 /

+0.36 (+0.24%)

GMAB Genmab
$36.05 /

+0.76 (+2.15%)

GMAB Genmab
$36.05 /

+0.76 (+2.15%)

07/02/20 Societe Generale
Genmab initiated with a Sell at Societe Generale
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Guggenheim
Guggenheim says Seattle Genetics' cervical cancer data 'a positive surprise'
06/25/20 Credit Suisse
Genmab downgraded to Neutral from Outperform at Credit Suisse
JNJ Johnson & Johnson
$148.32 /

+0.36 (+0.24%)

07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
07/13/20 H.C. Wainwright
Pacira price target raised to $68 from $63 at H.C. Wainwright
07/10/20 Jefferies
Pacira price target raised to $69 from $53 at Jefferies
07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
JNJ Johnson & Johnson
$148.32 /

+0.36 (+0.24%)

GMAB Genmab
$36.05 /

+0.76 (+2.15%)

  • 18
    Jul
JNJ Johnson & Johnson
$148.32 /

+0.36 (+0.24%)

JNJ Johnson & Johnson
$148.32 /

+0.36 (+0.24%)

GMAB Genmab
$36.05 /

+0.76 (+2.15%)

JNJ Johnson & Johnson
$148.32 /

+0.36 (+0.24%)

Over a month ago
Initiation
Genmab initiated with a Sell at Societe Generale » 11:56
07/02/20
07/02
11:56
07/02/20
11:56
GMAB

Genmab

$33.84 /

+0.76 (+2.30%)

Societe Generale analyst…

Societe Generale analyst Justin Smith initiated coverage of Genmab with a Sell rating and DKK 1,620 price target. While Smith acknowledges that 2019 was the seventh consecutive year of profitability and projects "a six-fold expansion" in annual sales from 2019-2030, he does not believe that the current share price appropriately discounts the company's portfolio concentration risk.

ShowHide Related Items >><<
GMAB Genmab
$33.84 /

+0.76 (+2.30%)

GMAB Genmab
$33.84 /

+0.76 (+2.30%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Guggenheim
Guggenheim says Seattle Genetics' cervical cancer data 'a positive surprise'
06/25/20 Credit Suisse
Genmab downgraded to Neutral from Outperform at Credit Suisse
06/19/20 RBC Capital
Genmab price target raised to $35 from $27 at RBC Capital
GMAB Genmab
$33.84 /

+0.76 (+2.30%)

  • 18
    Jul
GMAB Genmab
$33.84 /

+0.76 (+2.30%)

Recommendations
Seattle Genetics price target raised to $167 from $155 at SVB Leerink » 09:24
06/30/20
06/30
09:24
06/30/20
09:24
SGEN

Seattle Genetics

$164.41 /

-1.33 (-0.80%)

, GMAB

Genmab

$32.60 /

+0.57 (+1.78%)

, MRK

Merck

$76.07 /

+0.9 (+1.20%)

SVB Leerink analyst…

SVB Leerink analyst Andrew Berens raised the firm's price target on Seattle Genetics (SGEN) to $167 from $155 and keeps an Outperform rating on the shares. The analyst notes that Seattle Genetics and its partner Genmab (GMAB) announced top-line results from the innovaTV 204 Phase 2 study evaluating tisotumab vedotin in patients with recurrent or metastatic cervical cancer who have progressed after prior treatment. Berens believes most investors were looking for monotherapy data that could support an accelerated pathway, which this top-line release suggests is probable, given limited treatment options in these patients and the relatively low bar for efficacy. While detailed data are yet to be presented at an upcoming medical meeting in 2020, he is "encouraged" by the data, which suggest that TV could become the fourth commercial asset in Seattle Genetics' portfolio. Importantly, Berens thinks TV could be combined with Merck's (MRK) Keytruda as a key strategy going forward, which would expand Keytruda's therapeutic reach beyond its currently approved label for PD-L1+ cervical cancer patients.

ShowHide Related Items >><<
SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

MRK Merck
$76.07 /

+0.9 (+1.20%)

GMAB Genmab
$32.60 /

+0.57 (+1.78%)

SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

06/30/20 BMO Capital
Seattle Genetics price target raised to $186 from $174 at BMO Capital
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/30/20 Guggenheim
Guggenheim says Seattle Genetics' cervical cancer data 'a positive surprise'
06/26/20 Oppenheimer
Seattle Genetics price target raised to $200 from $175 at Oppenheimer
GMAB Genmab
$32.60 /

+0.57 (+1.78%)

06/25/20 Credit Suisse
Genmab downgraded to Neutral from Outperform at Credit Suisse
06/19/20 RBC Capital
Genmab price target raised to $35 from $27 at RBC Capital
06/17/20 UBS
AbbVie price target raised to $109 from $96 at UBS
MRK Merck
$76.07 /

+0.9 (+1.20%)

06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

MRK Merck
$76.07 /

+0.9 (+1.20%)

GMAB Genmab
$32.60 /

+0.57 (+1.78%)

  • 24
    Jul
  • 18
    Jul
MRK Merck
$76.07 /

+0.9 (+1.20%)

SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

MRK Merck
$76.07 /

+0.9 (+1.20%)

GMAB Genmab
$32.60 /

+0.57 (+1.78%)

MRK Merck
$76.07 /

+0.9 (+1.20%)

Recommendations
Guggenheim says Seattle Genetics' cervical cancer data 'a positive surprise' » 07:34
06/30/20
06/30
07:34
06/30/20
07:34
SGEN

Seattle Genetics

$164.41 /

-1.33 (-0.80%)

, GMAB

Genmab

$32.60 /

+0.57 (+1.78%)

Guggenheim analyst…

Guggenheim analyst Michael Schmidt said that Seattle Genetics (SGEN) and Genmab (GMAB) announced topline results from the Phase 2 trial of tisotumab vedotin in patients who have relapsed or progressed on or after prior treatment for recurrent or metastatic cervical cancer that he called a "positive surprise." The 24% ORR and 8.3 months mDOR reported in these patients "very likely clears the regulatory bar," according to Schmidt, who noted that Seattle Genetics management said they plan a potential submission of a BLA to support accelerated approval. This positive news may read through positively to the overall potential of tisotumab vedotin, which is being evaluated in first line mCC and other cancer types, added Schmidt, who raised his price target on Seattle Genetics shares to $183 from $175 and hiked his Genmab target to DKK 2,486 from DKK 2,350. He keeps Buy ratings on both stocks.

ShowHide Related Items >><<
SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

GMAB Genmab
$32.60 /

+0.57 (+1.78%)

SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

06/26/20 Oppenheimer
Seattle Genetics price target raised to $200 from $175 at Oppenheimer
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/01/20 Oppenheimer
Seattle Genetics price target raised to $175 from $146 at Oppenheimer
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
GMAB Genmab
$32.60 /

+0.57 (+1.78%)

06/25/20 Credit Suisse
Genmab downgraded to Neutral from Outperform at Credit Suisse
06/19/20 RBC Capital
Genmab price target raised to $35 from $27 at RBC Capital
06/17/20 UBS
AbbVie price target raised to $109 from $96 at UBS
06/12/20 JPMorgan
Genmab price target raised to DKK 1,950 from DKK 1,850 at JPMorgan
SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

GMAB Genmab
$32.60 /

+0.57 (+1.78%)

  • 24
    Jul
  • 18
    Jul
SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

GMAB Genmab
$32.60 /

+0.57 (+1.78%)

Downgrade
Genmab downgraded to Neutral from Outperform at Credit Suisse » 05:33
06/25/20
06/25
05:33
06/25/20
05:33
GMAB

Genmab

$33.20 /

+0.28 (+0.85%)

Credit Suisse analyst…

Credit Suisse analyst Trung Huynh downgraded Genmab to Neutral from Outperform with a DKK 2,235 price target.

ShowHide Related Items >><<
GMAB Genmab
$33.20 /

+0.28 (+0.85%)

GMAB Genmab
$33.20 /

+0.28 (+0.85%)

06/19/20 RBC Capital
Genmab price target raised to $35 from $27 at RBC Capital
06/17/20 UBS
AbbVie price target raised to $109 from $96 at UBS
06/12/20 JPMorgan
Genmab price target raised to DKK 1,950 from DKK 1,850 at JPMorgan
06/11/20 Barclays
Genmab price target raised to DKK 2,250 from DKK 2,150 at Barclays
GMAB Genmab
$33.20 /

+0.28 (+0.85%)

GMAB Genmab
$33.20 /

+0.28 (+0.85%)

Recommendations
Genmab price target raised to $35 from $27 at RBC Capital » 06:55
06/19/20
06/19
06:55
06/19/20
06:55
GMAB

Genmab

$30.97 /

-0.77 (-2.43%)

RBC Capital analyst…

RBC Capital analyst Kennen MacKay raised the firm's price target on Genmab to $35 from $27 and keeps an Outperform rating on the shares. The analyst cites "vast potential" for the company's epcoritamab in early-line NHL and also sees it as well-validated in late-line DLBCL, modeling potential for risk-unadjusted US and global sales of $2.4B and $4.6B respectively across lines of NHL.

ShowHide Related Items >><<
GMAB Genmab
$30.97 /

-0.77 (-2.43%)

GMAB Genmab
$30.97 /

-0.77 (-2.43%)

06/17/20 UBS
AbbVie price target raised to $109 from $96 at UBS
06/12/20 JPMorgan
Genmab price target raised to DKK 1,950 from DKK 1,850 at JPMorgan
06/11/20 Barclays
Genmab price target raised to DKK 2,250 from DKK 2,150 at Barclays
06/11/20 Guggenheim
Genmab deal with AbbVie topped high expectations, says Guggenheim
GMAB Genmab
$30.97 /

-0.77 (-2.43%)

GMAB Genmab
$30.97 /

-0.77 (-2.43%)

Recommendations
AbbVie price target raised to $109 from $96 at UBS » 06:16
06/17/20
06/17
06:16
06/17/20
06:16
ABBV

AbbVie

$96.16 /

+3.05 (+3.28%)

, GMAB

Genmab

$30.98 /

-0.13 (-0.42%)

UBS analyst Navin Jacob…

UBS analyst Navin Jacob raised the firm's price target on AbbVie (ABBV) to $109 from $96 and keeps a Buy rating on the shares. The analyst notes that following phase 2 data for ABBV-3373 in rheumatoid arthritis, he is increasing his probability of success to 50% from 35% and peak sales estimate to $1B from $700M. Jacob also cites AbbVie's announced collaboration with Genmab (GMAB) and includes his estimated $450M peak sales estimates for epcoritamab in his model.

ShowHide Related Items >><<
GMAB Genmab
$30.98 /

-0.13 (-0.42%)

ABBV AbbVie
$96.16 /

+3.05 (+3.28%)

ABBV AbbVie
$96.16 /

+3.05 (+3.28%)

06/11/20 Guggenheim
Genmab deal with AbbVie topped high expectations, says Guggenheim
06/11/20 Truist
Genmab price target raised to $39 from $36 at SunTrust
06/11/20 H.C. Wainwright
Genmab price target raised to $40 from $34 at H.C. Wainwright
06/10/20 Piper Sandler
AbbVie price target raised to $110 from $97 at Piper Sandler
GMAB Genmab
$30.98 /

-0.13 (-0.42%)

06/12/20 JPMorgan
Genmab price target raised to DKK 1,950 from DKK 1,850 at JPMorgan
06/11/20 Barclays
Genmab price target raised to DKK 2,250 from DKK 2,150 at Barclays
GMAB Genmab
$30.98 /

-0.13 (-0.42%)

ABBV AbbVie
$96.16 /

+3.05 (+3.28%)

ABBV AbbVie
$96.16 /

+3.05 (+3.28%)

GMAB Genmab
$30.98 /

-0.13 (-0.42%)

ABBV AbbVie
$96.16 /

+3.05 (+3.28%)

ABBV AbbVie
$96.16 /

+3.05 (+3.28%)

Recommendations
Genmab price target raised to DKK 1,950 from DKK 1,850 at JPMorgan » 11:53
06/12/20
06/12
11:53
06/12/20
11:53
GMAB

Genmab

$29.71 /

+0.5 (+1.71%)

JPMorgan analyst James…

JPMorgan analyst James Gordon raised the firm's price target on Genmab to DKK 1,950 from DKK 1,850 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
GMAB Genmab
$29.71 /

+0.5 (+1.71%)

GMAB Genmab
$29.71 /

+0.5 (+1.71%)

06/11/20 Barclays
Genmab price target raised to DKK 2,250 from DKK 2,150 at Barclays
06/11/20 Guggenheim
Genmab deal with AbbVie topped high expectations, says Guggenheim
06/11/20 Truist
Genmab price target raised to $39 from $36 at SunTrust
06/11/20 H.C. Wainwright
Genmab price target raised to $40 from $34 at H.C. Wainwright
GMAB Genmab
$29.71 /

+0.5 (+1.71%)

GMAB Genmab
$29.71 /

+0.5 (+1.71%)

Recommendations
Genmab price target raised to DKK 2,250 from DKK 2,150 at Barclays » 14:04
06/11/20
06/11
14:04
06/11/20
14:04
GMAB

Genmab

$29.51 /

-0.67 (-2.22%)

Barclays analyst Emily…

Barclays analyst Emily Field raised the firm's price target on Genmab to DKK 2,250 from DKK 2,150 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
GMAB Genmab
$29.51 /

-0.67 (-2.22%)

GMAB Genmab
$29.51 /

-0.67 (-2.22%)

06/11/20 Guggenheim
Genmab deal with AbbVie topped high expectations, says Guggenheim
06/11/20 Truist
Genmab price target raised to $39 from $36 at SunTrust
06/11/20 H.C. Wainwright
Genmab price target raised to $40 from $34 at H.C. Wainwright
06/10/20 Piper Sandler
AbbVie price target raised to $110 from $97 at Piper Sandler
GMAB Genmab
$29.51 /

-0.67 (-2.22%)

GMAB Genmab
$29.51 /

-0.67 (-2.22%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.